Study of Bevacizumab + Irinotecan + S-1 therapy in metastatic colorectal cancer with KRAS mutant type
- Conditions
- Metastatic colorectal cancer
- Registration Number
- JPRN-UMIN000004630
- Lead Sponsor
- Tsuchiura kyodo general hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 25
Not provided
(1) History of severe allergy (2) Active double cancer (3) Severe infectious disease (4) Intestinal tract paralysis or intestinal obstruction (5) Uncontrolled hypertention (6) Sever comorbidity(interstitial lung disease or pulmonary fibrosis, heart failure, renal failure, liver failure, etc) (7) Massive pleural or abdominal effusion (8) Patient with the diarrhea (9) Symptomatic brain metastases (10) Women who are unwilling to avoid pregnancy. Women who are pregnant or breastfeeding. Women with a positive pregnancy test (11) Severe mental disorder (12) Systemic administration of corticosteroids (13) Uric protein 2+ (14) Prior radiotherapy for primary and metastases tumors (15) Thrombosis, cerebral infraction, cardiac infraction or pulmonary infraction within 6 months (16) Patients who underwent surgery within 4 weeks (17) Systemic administration of antiplatelet drug (18) Patients with known bleeding disorders or clotting disorder (19) Any other cases who are regarded as inadequate for study enrollmet by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method